The disruption of the immune system by viral attack is a major influencing factor in the lethality of COVID-19. Baicalein is one of the key effective compounds against COVID-19. The molecular mechanisms regarding the anti-inflammatory properties of Baicalein are still unclear. In this study, we established LPS-induced mice to elucidate the role of Baicalein in the treatment of acute lung injury (ALI) and its potential molecular mechanisms. In vivo experiments showed that Baicalein could significantly ameliorate LPS-induced acute lung injury and reduce proteinous edema in lung tissue. In addition, Baicalein inhibited M1 macrophage polarization, promote M2 macrophage polarization, and regulate inflammatory responses. Furthermore, Baicalein could inhibit the expression of protein molecules associated with pyroptosis and mitigate the lung tissue injury. In summary, we revealed the therapeutic effects of Baicalein in acute lung injury, providing the theoretical basis for its clinical application.
Acute Lung Injury , Flavanones , Lipopolysaccharides , Macrophages , Pyroptosis , Flavanones/pharmacology , Flavanones/therapeutic use , Animals , Pyroptosis/drug effects , Lipopolysaccharides/toxicity , Mice , Acute Lung Injury/chemically induced , Acute Lung Injury/drug therapy , Macrophages/drug effects , Macrophages/immunology , Male , Mice, Inbred C57BL , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Disease Models, Animal , Pneumonia/drug therapy , Pneumonia/chemically induced , Lung/drug effects , Lung/pathology , COVID-19 Drug Treatment , COVID-19/immunology
